Galera Therapeutics, Inc.

NasdaqGM:GRTX Stock Report

Market Cap: US$11.3m

Galera Therapeutics Dividend

Dividend criteria checks 0/6

Galera Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.09
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Feb 15
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Oct 25
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics appoints chief medical officer

Sep 01

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24
Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05
Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17
Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics EPS beats by $0.08

Nov 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if GRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRTX's dividend payments have been increasing.


Dividend Yield vs Market

Galera Therapeutics Dividend Yield vs Market
How does GRTX dividend yield compare to the market?
SegmentDividend Yield
Company (GRTX)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (GRTX)0%

Notable Dividend: Unable to evaluate GRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate GRTX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRTX has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.